S&P 500   3,303.14 (+1.74%)
DOW   27,213.86 (+1.49%)
QQQ   271.79 (+2.41%)
AAPL   112.16 (+3.64%)
MSFT   208.63 (+2.68%)
FB   254.88 (+2.14%)
GOOGL   1,442.58 (+1.39%)
AMZN   3,091.57 (+2.38%)
TSLA   403.74 (+4.11%)
NVDA   512.96 (+3.85%)
BABA   270.75 (+0.38%)
CGC   14.20 (-0.49%)
GE   6.15 (+1.49%)
MU   49.03 (-0.89%)
AMD   78.09 (+2.99%)
T   28.04 (+0.00%)
F   6.54 (-1.80%)
ACB   5.01 (-3.65%)
GILD   62.42 (+0.27%)
NFLX   483.80 (+2.27%)
DIS   123.80 (+1.07%)
BAC   23.49 (+0.64%)
BA   154.79 (+5.98%)
S&P 500   3,303.14 (+1.74%)
DOW   27,213.86 (+1.49%)
QQQ   271.79 (+2.41%)
AAPL   112.16 (+3.64%)
MSFT   208.63 (+2.68%)
FB   254.88 (+2.14%)
GOOGL   1,442.58 (+1.39%)
AMZN   3,091.57 (+2.38%)
TSLA   403.74 (+4.11%)
NVDA   512.96 (+3.85%)
BABA   270.75 (+0.38%)
CGC   14.20 (-0.49%)
GE   6.15 (+1.49%)
MU   49.03 (-0.89%)
AMD   78.09 (+2.99%)
T   28.04 (+0.00%)
F   6.54 (-1.80%)
ACB   5.01 (-3.65%)
GILD   62.42 (+0.27%)
NFLX   483.80 (+2.27%)
DIS   123.80 (+1.07%)
BAC   23.49 (+0.64%)
BA   154.79 (+5.98%)
S&P 500   3,303.14 (+1.74%)
DOW   27,213.86 (+1.49%)
QQQ   271.79 (+2.41%)
AAPL   112.16 (+3.64%)
MSFT   208.63 (+2.68%)
FB   254.88 (+2.14%)
GOOGL   1,442.58 (+1.39%)
AMZN   3,091.57 (+2.38%)
TSLA   403.74 (+4.11%)
NVDA   512.96 (+3.85%)
BABA   270.75 (+0.38%)
CGC   14.20 (-0.49%)
GE   6.15 (+1.49%)
MU   49.03 (-0.89%)
AMD   78.09 (+2.99%)
T   28.04 (+0.00%)
F   6.54 (-1.80%)
ACB   5.01 (-3.65%)
GILD   62.42 (+0.27%)
NFLX   483.80 (+2.27%)
DIS   123.80 (+1.07%)
BAC   23.49 (+0.64%)
BA   154.79 (+5.98%)
S&P 500   3,303.14 (+1.74%)
DOW   27,213.86 (+1.49%)
QQQ   271.79 (+2.41%)
AAPL   112.16 (+3.64%)
MSFT   208.63 (+2.68%)
FB   254.88 (+2.14%)
GOOGL   1,442.58 (+1.39%)
AMZN   3,091.57 (+2.38%)
TSLA   403.74 (+4.11%)
NVDA   512.96 (+3.85%)
BABA   270.75 (+0.38%)
CGC   14.20 (-0.49%)
GE   6.15 (+1.49%)
MU   49.03 (-0.89%)
AMD   78.09 (+2.99%)
T   28.04 (+0.00%)
F   6.54 (-1.80%)
ACB   5.01 (-3.65%)
GILD   62.42 (+0.27%)
NFLX   483.80 (+2.27%)
DIS   123.80 (+1.07%)
BAC   23.49 (+0.64%)
BA   154.79 (+5.98%)
Log in
NASDAQ:AKTX

Akari Therapeutics Stock Forecast, Price & News

$1.61
+0.01 (+0.63 %)
(As of 09/25/2020 09:37 AM ET)
Add
Compare
Today's Range
$1.61
Now: $1.61
$1.61
50-Day Range
$1.58
MA: $1.74
$2.03
52-Week Range
$0.87
Now: $1.61
$2.79
Volume15 shs
Average Volume259,639 shs
Market Capitalization$25.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.
Read More
Akari Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKTX
CUSIPN/A
Phone646-350-0702

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.11) per share

Profitability

Net Income$-17,110,000.00

Miscellaneous

Employees17
Market Cap$25.53 million
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
$1.61
+0.01 (+0.63 %)
(As of 09/25/2020 09:37 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

How has Akari Therapeutics' stock been impacted by Coronavirus?

Akari Therapeutics' stock was trading at $1.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AKTX shares have increased by 4.5% and is now trading at $1.61.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Akari Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Akari Therapeutics
.

When is Akari Therapeutics' next earnings date?

Akari Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Akari Therapeutics
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics PLC (NASDAQ:AKTX) announced its earnings results on Tuesday, September, 1st. The biopharmaceutical company reported ($0.28) earnings per share for the quarter.
View Akari Therapeutics' earnings history
.

What price target have analysts set for AKTX?

1 brokerages have issued 12 month price targets for Akari Therapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Akari Therapeutics' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 210.6% from the stock's current price.
View analysts' price targets for Akari Therapeutics
.

Who are some of Akari Therapeutics' key competitors?

What other stocks do shareholders of Akari Therapeutics own?

Who are Akari Therapeutics' key executives?

Akari Therapeutics' management team includes the following people:
  • Dr. Ray Prudo, Exec. Chairman (Age 74)
  • Mr. Clive Richardson, COO, Director & Interim CEO (Age 54)
  • Mr. Dov Elefant, Chief Financial Officer (Age 52)
  • Dr. Miles Nunn, Chief Scientific Officer

What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include United Asset Strategies Inc. (1.89%), Virtu Financial LLC (0.11%), PNC Financial Services Group Inc. (0.08%) and PNC Financial Services Group Inc. (0.08%).
View institutional ownership trends for Akari Therapeutics
.

Which major investors are buying Akari Therapeutics stock?

AKTX stock was purchased by a variety of institutional investors in the last quarter, including United Asset Strategies Inc., Virtu Financial LLC, PNC Financial Services Group Inc., and PNC Financial Services Group Inc..
View insider buying and selling activity for Akari Therapeutics
.

How do I buy shares of Akari Therapeutics?

Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.61.

How big of a company is Akari Therapeutics?

Akari Therapeutics has a market capitalization of $25.53 million. The biopharmaceutical company earns $-17,110,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Akari Therapeutics employs 17 workers across the globe.

What is Akari Therapeutics' official website?

The official website for Akari Therapeutics is www.akaritx.com.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 646-350-0702 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.